Great Lakes Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Great Lakes Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.49M	Sell	48,180 -4,434	-8%	-$226K	0.02%	374
2025 Q4	$2.61M	Sell	52,614 -18,617	-26%	-$905K	0.02%	373
2025 Q3	$3.4M	Sell	71,231 -70,950	-50%	-$2.86M	0.03%	331
2025 Q2	$4.48M	Sell	142,181 -21,399	-13%	-$686K	0.04%	310
2025 Q1	$5.36M	Sell	163,580 -5,977	-4%	-$212K	0.05%	272
2024 Q4	$6.13M	Buy	+169,557	New	+$5.97M	0.05%	270
2021 Q4	–	Sell	-8,102	Closed	-$216K	–	727
2021 Q3	$216K	Buy	+8,102	New	+$217K	﹤0.01%	640

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Great Lakes Advisors's SUPN Position: Q1 2026 in Review

Great Lakes Advisors reduced its Supernus Pharmaceuticals (SUPN) stake by 8.4% in Q1 2026, selling an estimated $226K and leaving 48,180 shares worth $2.49M. The position accounts for 0.02% of the portfolio, ranked #374.

Great Lakes Advisors first reported a position in SUPN in Q3 2021 and has held it in 7 quarters since. The position peaked at $6.13M in Q4 2024. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Great Lakes Advisors held 48,180 shares of Supernus Pharmaceuticals worth $2.49M as of Q1 2026.
Great Lakes Advisors sold 4,434 Supernus Pharmaceuticals shares in Q1 2026, an estimated $226K.
Supernus Pharmaceuticals made up 0.02% of Great Lakes Advisors's portfolio in Q1 2026, its #374 holding.
Great Lakes Advisors first reported a position in Supernus Pharmaceuticals in Q3 2021 and has held it in 7 quarters since.
Great Lakes Advisors's Supernus Pharmaceuticals position peaked at $6.13M in Q4 2024.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Great Lakes Advisors's 13F filing for Q1 2026, filed 12 May 2026.